抗癌抗生素三糖素A和LL-D49194α1之间的不同DNA结合和损伤模式
Ruo-Qin Gao1, Xiao-Dong Hu1, Qiang Zhou1
1State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200032, China.
JACS Au
|September 27, 2024
概括
三糖素A (TXN) 和它的类似物LL-D49194α1 (LLD) 与双链DNA (dsDNA) 结合. 与TXN相比,LLD会导致更大的DNA损伤和变性,导致明显的生物效应.
科学领域:
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
- 结构生物学 结构生物学
背景情况:
- 三糖素A (TXN) 是一种强大的细胞毒性抗生素.
- LL-D49194α1 (LLD) 是一种TXN模拟物,具有明显的糖化模式,此前在临床试验中.
- 在LLD的DNA结合机制仍然不清楚.
研究的目的:
- 阐明与TXN和LLD结合的dsDNA的高分辨率溶液结构.
- 为了比较TXN和LLD的DNA结合和破坏作用.
- 了解不同DNA相互作用的生物学后果.
主要方法:
- 化dDNA及其与TXN和LLD复合物的高分辨率溶液结构确定.
- 生物化学测试用于评估DNA稳定性和损伤.
- 对TXN和LLD基化dDNA进行比较分析.
主要成果:
- 该研究确定了dsDNA与TXN和LLD共同结合的结构.
- TXN-基化dsDNA保持了螺旋形状.
- 与TXN基化dDNA相比,LLD基化dDNA的稳定性降低,变性增加.
- 尽管在体外细胞毒性较低,但LLD诱导了更大的DNA损伤.
结论:
- 在TXN和LLD之间糖替代的差异显著改变了它们的DNA结合和破坏性特性.
- 由于LLD与dsDNA的明显相互作用,导致DNA更大的不稳定性和变性,从而产生独特的生物效应.
- 这项研究为潜在的治疗开发提供了TXN类似物结构-活性关系的见解.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:25Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:25Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K